Company registration number 07179157 (England and Wales)
ACCULABS DIAGNOSTICS UK LTD
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025
PAGES FOR FILING WITH REGISTRAR
ACCULABS DIAGNOSTICS UK LTD
CONTENTS
Page
Balance sheet
1 - 2
Notes to the financial statements
3 - 8
ACCULABS DIAGNOSTICS UK LTD
BALANCE SHEET
AS AT
31 MARCH 2025
31 March 2025
- 1 -
2025
2024
Notes
£
£
£
£
Fixed assets
Intangible assets
3
566,969
534,645
Tangible assets
4
349,734
515,598
916,703
1,050,243
Current assets
Stocks
201,781
123,319
Debtors
5
847,513
924,391
Cash at bank and in hand
372
13,246
1,049,666
1,060,956
Creditors: amounts falling due within one year
6
(1,882,099)
(1,780,717)
Net current liabilities
(832,433)
(719,761)
Total assets less current liabilities
84,270
330,482
Creditors: amounts falling due after more than one year
7
(90,720)
(184,759)
Net (liabilities)/assets
(6,450)
145,723
Capital and reserves
Called up share capital
2
2
Profit and loss reserves
(6,452)
145,721
Total equity
(6,450)
145,723
ACCULABS DIAGNOSTICS UK LTD
BALANCE SHEET (CONTINUED)
AS AT
31 MARCH 2025
31 March 2025
- 2 -

For the financial year ended 31 March 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The directors of the company have elected not to include a copy of the profit and loss account within the financial statements.true

The financial statements were approved by the board of directors and authorised for issue on 15 December 2025 and are signed on its behalf by:
Mr C Gordon
Director
Company registration number 07179157 (England and Wales)
ACCULABS DIAGNOSTICS UK LTD
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025
- 3 -
1
Accounting policies
Company information

Acculabs Diagnostics UK Ltd is a private company limited by shares incorporated in England and Wales. The registered office is Unit 12, Wynyard Park Business Village, Wynyard Park, Billingham, Co Durham, TS22 5TB.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

1.2
Going concern

The company reports net current liabilties of £832,433 and net liabilities of £6,450, however at the time of approving the financial statements, the directors have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. Thus the directors continue to adopt the going concern basis of accounting in preparing the financial statements.

1.3
Turnover

Turnover comprises the fair value of the consideration received or receivable for the sale of goods and provision of services in the ordinary course of the company’s activities. Turnover is shown net of value added tax, returns, rebates and discounts.

1.4
Research and development expenditure

Research expenditure is written off against profits in the year in which it is incurred.

 

Development costs are capitalised when the project is clearly defined, the expenditure is separately identifiable, the outcome is assessed as technically feasible, and the company has the intention and ability to complete the development and use or sell the resulting asset.

1.5
Intangible fixed assets other than goodwill

Intangible assets acquired separately from a business are recognised at cost and are subsequently measured at cost less accumulated amortisation and accumulated impairment losses.

 

Capitalised development costs are recognised as intangible assets and are amortised on a straight-line basis over their estimated useful life.

 

Costs that do not meet the criteria for capitalisation are expensed as incurred.

 

The carrying value of capitalised development costs is reviewed annually for indicators of impairment, and written down where necessary.

Amortisation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Development costs
10% straight line
Assets under construction
not amortised
ACCULABS DIAGNOSTICS UK LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
1
Accounting policies
(Continued)
- 4 -
1.6
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Land and buildings
20% straight line
Fixtures and fittings
20% straight line
Office equipment
20% straight line
Laboratory Equipment
20% straight line

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

1.7
Impairment of fixed assets

At each reporting period end date, the company reviews the carrying amounts of its tangible and intangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). Where it is not possible to estimate the recoverable amount of an individual asset, the company estimates the recoverable amount of the cash-generating unit to which the asset belongs.

Recoverable amount is the higher of fair value less costs to sell and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset for which the estimates of future cash flows have not been adjusted.

 

If the recoverable amount of an asset (or cash-generating unit) is estimated to be less than its carrying amount, the carrying amount of the asset (or cash-generating unit) is reduced to its recoverable amount. An impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the impairment loss is treated as a revaluation decrease.

1.8
Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the stocks to their present location and condition.

 

Stocks held for distribution at no or nominal consideration are measured at the lower of cost and replacement cost, adjusted where applicable for any loss of service potential.

1.9
Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

ACCULABS DIAGNOSTICS UK LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
1
Accounting policies
(Continued)
- 5 -
1.10
Financial instruments
Basic financial assets

Trade debtors are amounts due from customers for merchandise sold or services performed in the ordinary course of business.

 

Trade debtors are recognised initially at the transaction price. They are subsequently measured at amortised cost using the effective interest method, less provision for impairment. A provision for the impairment of trade debtors is established when there is objective evidence that the company will not be able to collect all amounts due according to the original terms of the receivables.

Classification of financial liabilities

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the company does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.

 

Trade creditors are recognised initially at the transaction price and subsequently measured at amortised cost using the effective interest method.

1.11
Equity instruments

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

1.12
Taxation

The tax expense for the period comprises current and deferred tax. Tax is recognised in profit or loss, except that a charge attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income.

Current tax

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates taxable income.

Deferred tax

Deferred tax is recognised in respect of all timing differences between taxable profits and profits reported in the financial statements. Unrelieved tax losses and other deferred tax assets are recognised when it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date and that are expected to apply to the reversal of the timing difference.

1.13
Employee benefits

The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets.

 

The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.

1.14
Retirement benefits

Contributions to defined contribution plans are recognised as employee benefit expense when they are due. If contribution payments exceed the contribution due for service, the excess is recognised as a prepayment.

ACCULABS DIAGNOSTICS UK LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
1
Accounting policies
(Continued)
- 6 -
1.15
Leases
As lessee

Leases in which substantially all the risks and rewards of ownership are retained by the lessor are classified as operating leases. Payments made under operating leases are charged to profit or loss on a straight-line basis over the period of the lease.

 

Leases are classified as finance leases whenever the terms of the lease transfer substantially all the risks and rewards of ownership to the lessee.

 

Assets held under finance leases are recognised at the lower of their fair value at inception of the lease and the present value of the minimum lease payments. These assets are depreciated on a straight-line basis over the shorter of the useful life of the asset and the lease term. The corresponding liability to the lessor is included in the statement of financial position as a finance lease obligation.

 

Lease payments are apportioned between finance costs in the income statement and reduction of the lease obligation so as to achieve a constant periodic rate of interest on the remaining balance of the liability.

2
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2025
2024
Number
Number
Total
50
43
3
Intangible fixed assets
Development costs
Assets under construction
Total
£
£
£
Cost
At 1 April 2024
484,271
200,620
684,891
Additions
67,501
20,000
87,501
At 31 March 2025
551,772
220,620
772,392
Amortisation and impairment
At 1 April 2024
150,246
-
0
150,246
Amortisation charged for the year
55,177
-
0
55,177
At 31 March 2025
205,423
-
0
205,423
Carrying amount
At 31 March 2025
346,349
220,620
566,969
At 31 March 2024
334,025
200,620
534,645
ACCULABS DIAGNOSTICS UK LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
- 7 -
4
Tangible fixed assets
Land and buildings
Fixtures and fittings
Office equipment
Laboratory Equipment
Total
£
£
£
£
£
Cost
At 1 April 2024
2,136
124,075
87,873
850,736
1,064,820
Additions
-
0
9,481
1,861
34,980
46,322
At 31 March 2025
2,136
133,556
89,734
885,716
1,111,142
Depreciation and impairment
At 1 April 2024
2,136
99,035
76,956
371,095
549,222
Depreciation charged in the year
-
0
25,763
12,778
173,645
212,186
At 31 March 2025
2,136
124,798
89,734
544,740
761,408
Carrying amount
At 31 March 2025
-
0
8,758
-
0
340,976
349,734
At 31 March 2024
-
0
25,040
10,917
479,641
515,598
5
Debtors
2025
2024
Amounts falling due within one year:
£
£
Trade debtors
574,712
614,189
Corporation tax recoverable
14,956
-
0
Other debtors
131,318
69,021
Prepayments and accrued income
122,599
150,114
843,585
833,324
2025
2024
Amounts falling due after more than one year:
£
£
Deferred tax asset
3,928
91,067
Total debtors
847,513
924,391
ACCULABS DIAGNOSTICS UK LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
- 8 -
6
Creditors: amounts falling due within one year
2025
2024
£
£
Bank loans and overdrafts
102,906
135,746
Obligations under finance leases
24,194
16,189
Other borrowings
25,809
31,906
Trade creditors
807,225
664,604
Corporation tax
16,825
-
0
Other taxation and social security
296,382
314,025
Other creditors
529,981
553,426
Accruals and deferred income
78,777
64,821
1,882,099
1,780,717

Obligations under finance leases are secured over the assets to which they relate.

7
Creditors: amounts falling due after more than one year
2025
2024
£
£
Bank loans and overdrafts
-
0
68,691
Obligations under finance leases
54,887
42,653
Other borrowings
35,833
73,415
90,720
184,759

Obligations under finance leases are secured over the assets to which they relate.

 

8
Directors' transactions
Description
% Rate
Opening balance
Amounts advanced
Amounts repaid
Closing balance
£
£
£
£
Mr C Gordon
-
32,898
62,021
(12,168)
82,751
Dr R Singh
-
36,123
375
(5,300)
31,198
69,021
62,396
(17,468)
113,949

At the year end the company was also owed £20,000 by Mrs S Gordon. Mrs S Gordon is the wife of Mr C Gordon.

 

Mr C Gordon has provided personal guarantees in respect of certain company finance lease contracts and invoice discounting liabilities.

2025-03-312024-04-01falsefalsefalse15 December 2025CCH SoftwareCCH Accounts Production 2025.300No description of principal activityMr C GordonDr R SinghMrs S  Gordon071791572024-04-012025-03-31071791572025-03-31071791572024-03-3107179157core:DevelopmentCostsCapitalisedDevelopmentExpenditure2025-03-3107179157core:Non-standardIntangibleAssetClass1ComponentIntangibleAssetsOtherThanGoodwill2025-03-3107179157core:DevelopmentCostsCapitalisedDevelopmentExpenditure2024-03-3107179157core:Non-standardIntangibleAssetClass1ComponentIntangibleAssetsOtherThanGoodwill2024-03-3107179157core:LandBuildings2025-03-3107179157core:FurnitureFittings2025-03-3107179157core:ComputerEquipment2025-03-3107179157core:Non-standardPPEClass1ComponentTotalPropertyPlantEquipment2025-03-3107179157core:LandBuildings2024-03-3107179157core:FurnitureFittings2024-03-3107179157core:ComputerEquipment2024-03-3107179157core:Non-standardPPEClass1ComponentTotalPropertyPlantEquipment2024-03-3107179157core:CurrentFinancialInstrumentscore:WithinOneYear2025-03-3107179157core:CurrentFinancialInstrumentscore:WithinOneYear2024-03-3107179157core:WithinOneYear2025-03-3107179157core:WithinOneYear2024-03-3107179157core:AfterOneYear2025-03-3107179157core:AfterOneYear2024-03-3107179157core:CurrentFinancialInstruments2025-03-3107179157core:CurrentFinancialInstruments2024-03-3107179157core:Non-currentFinancialInstruments2025-03-3107179157core:Non-currentFinancialInstruments2024-03-3107179157core:ShareCapital2025-03-3107179157core:ShareCapital2024-03-3107179157core:RetainedEarningsAccumulatedLosses2025-03-3107179157core:RetainedEarningsAccumulatedLosses2024-03-3107179157bus:Director12024-04-012025-03-3107179157core:IntangibleAssetsOtherThanGoodwill2024-04-012025-03-3107179157core:DevelopmentCostsCapitalisedDevelopmentExpenditure2024-04-012025-03-3107179157core:Non-standardIntangibleAssetClass1ComponentIntangibleAssetsOtherThanGoodwill2024-04-012025-03-3107179157core:LandBuildingscore:LongLeaseholdAssets2024-04-012025-03-3107179157core:FurnitureFittings2024-04-012025-03-3107179157core:ComputerEquipment2024-04-012025-03-3107179157core:Non-standardPPEClass1ComponentTotalPropertyPlantEquipment2024-04-012025-03-31071791572023-04-012024-03-3107179157core:DevelopmentCostsCapitalisedDevelopmentExpenditure2024-03-3107179157core:Non-standardIntangibleAssetClass1ComponentIntangibleAssetsOtherThanGoodwill2024-03-31071791572024-03-3107179157core:DevelopmentCostsCapitalisedDevelopmentExpenditurecore:ExternallyAcquiredIntangibleAssets2024-04-012025-03-3107179157core:Non-standardIntangibleAssetClass1ComponentIntangibleAssetsOtherThanGoodwillcore:ExternallyAcquiredIntangibleAssets2024-04-012025-03-3107179157core:ExternallyAcquiredIntangibleAssets2024-04-012025-03-3107179157core:LandBuildingscore:LeasedAssetsHeldAsLessee2024-03-3107179157core:FurnitureFittings2024-03-3107179157core:ComputerEquipment2024-03-3107179157core:Non-standardPPEClass1ComponentTotalPropertyPlantEquipment2024-03-3107179157core:LandBuildingscore:LeasedAssetsHeldAsLessee2025-03-3107179157core:LandBuildingscore:LeasedAssetsHeldAsLessee2024-04-012025-03-3107179157bus:PrivateLimitedCompanyLtd2024-04-012025-03-3107179157bus:SmallCompaniesRegimeForAccounts2024-04-012025-03-3107179157bus:FRS1022024-04-012025-03-3107179157bus:AuditExemptWithAccountantsReport2024-04-012025-03-3107179157bus:Director22024-04-012025-03-3107179157bus:CompanySecretary12024-04-012025-03-3107179157bus:FullAccounts2024-04-012025-03-31xbrli:purexbrli:sharesiso4217:GBP